AUPH Aurinia Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AUPH

Price (delayed)

$15.18

Market cap

$2.02B

P/E Ratio

6.43

Dividend/share

N/A

EPS

$2.36

Enterprise value

$1.9B

?
Relative Growth: Rel. Growth: 89
Relative Strength: Rel. Strength: 42
Relative Valuation: Rel. Valuation: 91
Relative Profitability: Rel. Profitability: 99

Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the ...

Highlights
AUPH's equity has soared by 83% year-on-year and by 8% since the previous quarter
The P/E is 36% less than the last 4 quarters average of 10.1
Sector: Healthcare
Industry: Biotechnology
Website: http://www.auriniapharma.com
Peers: QURE LXRX

Key stats

What are the main financial stats of AUPH

AUPH stock price

How has the Aurinia Pharmaceuticals stock price performed over time
Intraday
-1.75%
1 week
-5.89%
1 month
-5.3%
1 year
26.39%
YTD
-4.83%
QTD
-10.55%

Financial performance

How have Aurinia Pharmaceuticals's revenue and profit performed over time
Revenue
$311.51M
Gross profit
$281.47M
Operating income
$150.75M
Net income
$314.11M
Gross margin
90.4%
Net margin
100.8%
The operating income has soared by 190% year-on-year and by 21% since the previous quarter
The operating margin has soared by 142% YoY and by 16% from the previous quarter
Aurinia Pharmaceuticals's gross profit has increased by 21% YoY and by 5% from the previous quarter
The revenue has increased by 20% YoY and by 4.4% from the previous quarter

Price vs fundamentals

How does AUPH's price correlate with its fundamentals

Growth

What is Aurinia Pharmaceuticals's growth rate over time

Valuation

What is Aurinia Pharmaceuticals stock price valuation
AUPH P/E details
P/E
6.43
P/B
3.17
P/S
6.34
EV/EBIT
11.58
EV/EBITDA
10.36
EV/Sales
6.11
The P/E is 36% less than the last 4 quarters average of 10.1
Aurinia Pharmaceuticals's EPS has increased by 6% QoQ
AUPH's equity has soared by 83% year-on-year and by 8% since the previous quarter
The price to book (P/B) is 14% lower than the last 4 quarters average of 3.7 and 12% lower than the 5-year quarterly average of 3.6
The stock's P/S is 48% less than its 5-year quarterly average of 12.3 and 5% less than its last 4 quarters average of 6.7
The revenue has increased by 20% YoY and by 4.4% from the previous quarter

Efficiency

How efficient is Aurinia Pharmaceuticals business performance
Aurinia Pharmaceuticals's return on sales has surged by 105% YoY and by 14% QoQ
AUPH's ROIC has soared by 94% year-on-year and by 13% since the previous quarter
The ROE has decreased by 9% from the previous quarter
The company's return on assets fell by 6% QoQ

Dividends

What is AUPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AUPH.

Financial health

How did Aurinia Pharmaceuticals financials performed over time
Aurinia Pharmaceuticals's total assets has surged by 58% YoY and by 9% QoQ
The total liabilities has increased by 13% from the previous quarter and by 6% YoY
Aurinia Pharmaceuticals's debt is 90% lower than its equity
AUPH's equity has soared by 83% year-on-year and by 8% since the previous quarter
The company's debt to equity has shrunk by 58% YoY and by 17% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.